Issue 01 · Mechanism-first
Sourced, skeptical, mechanism-first coverage of the peptide era.
We read the primary literature so the meme doesn't get ahead of the mechanism.
Lead story
Shaquille O'Neal's GLP-1 — for sleep apnea, not a weight story
A 2011 Harvard sleep study, a Zepbound prescription, and an Eli Lilly campaign disclosure.
Read the piece
Profiles
Public-figure reportage
Sourced accounts of public figures who have publicly discussed GLP-1 medications — FDA-approved prescription drugs, not research peptides.
Serena Williams and the postpartum GLP-1 conversation
An August 2025 disclosure, a paid telehealth partnership, and a public reframe of weight as biology rather than willpower.
Oprah Winfrey and the 'tool, not willpower' reframe
A December 2023 confirmation, an ABC primetime special, and a board resignation to remove a conflict of interest.
Elon Musk, 'Ozempic Santa,' and the access debate
A Christmas 2024 social-media post, a follow-up correction, and an argument for making GLP-1 drugs cheap.
The feed
16 pieces
How to read a peptide Certificate of Analysis
A field guide to the document every research-peptide seller publishes and almost no reader interrogates. Batch numbers, HPLC, mass spec, and the difference between a real third-party report and a decorative PDF.
What 'research use only' actually means
Four words that started life describing bench reagents and now travel on the outside of consumer-facing peptide vials. The legal weight is smaller than the label implies.
Why third-party purity testing matters
Counterfeits, contaminants, and the reason 'looks like the label' is not evidence of anything.
BPC-157: what the research has actually examined
The rodent literature is large and specific. The clinical literature is small and inconclusive. Both facts are worth reading carefully.
TB-500: what the research has actually examined
A synthetic fragment of thymosin beta-4 with a preclinical footprint in tissue repair models, an equine racing regulatory history, and almost no controlled human data.
GHK-Cu: what the research has actually examined
A copper-binding tripeptide with a long biochemistry, a substantial cosmetic-ingredient literature, and a much smaller injectable clinical footprint.
CJC-1295 and Ipamorelin: what the research has examined
A GHRH analog and a selective ghrelin-mimetic. The short-term pharmacodynamic story is well characterized; the chronic clinical story for the marketed use case is not.
GLP-1 compounds in longevity and performance circles: trial data versus the hype
The peer-reviewed program for semaglutide and tirzepatide is one of the largest in modern pharmacology. The way it gets discussed in longevity and biohacking media is a different document.
The peptide reclassification, explained
The February 2026 regulatory changes in plain language: what shifted, what did not, and which categories of buyer and seller the changes actually reach.
The GLP-1 moment reaches sport
What started as a diabetes and obesity story is now turning up in locker rooms, broadcast booths, and anti-doping monitoring lists.
What peptides actually are
Short chains of amino acids. Everything else — the marketing, the categories, the legality — sits on top of that one sentence.
BPC-157: striking animal data, almost no human data
The preclinical literature is large. The clinical literature, as of early 2026, is essentially absent — and regulators have noticed.
Sleep, recovery, and the secretagogue story
Growth hormone pulses during deep sleep. That fact gets stretched a long way in marketing copy for peptides that target the same axis.
'Research use only,' explained
Four words that do a lot of regulatory and legal work — and that mean less than the label implies.
Why third-party testing matters
Identity, potency, sterility, endotoxin. The four words you should know before reading a Certificate of Analysis.
What 'compounded' actually means
The word covers a regulated pharmacy practice, an emergency shortage workaround, and — in 2025 — an FDA enforcement target. They are not the same thing.
Newsletter
The science, in your inbox.
Sourced explainers on peptides and biohacking. No hype, no claims — just the research, parsed. One email a week.
Research summaries, not medical advice. Unsubscribe anytime.